Shanghai RAAS Blood Products Co Ltd
Shanghai RAAS Blood Products Co Ltd operates in the pharmaceuticals sector, generating revenue through the production and sale of blood-derived medical products.
Business. Shanghai RAAS Blood Products Co Ltd (002252.SZ) is a pharmaceutical company headquartered in Shanghai that operates within the healthcare sector. The firm is primarily engaged in the research, development, and sale of blood products and related pharmaceuticals. It is listed on the Shenzhen Stock Exchange under the ticker symbol 002252.SZ. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Shanghai RAAS Blood Products Co Ltd (002252.SZ) is a pharmaceutical company headquartered in Shanghai that operates within the healthcare sector. The firm is primarily engaged in the research, development, and sale of blood products and related pharmaceuticals. It is listed on the Shenzhen Stock Exchange under the ticker symbol 002252.SZ. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Shanghai RAAS Blood Products Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.12 and a robust current ratio of 3.64, indicating strong short-term liquidity coverage. The company holds total assets of 37.78 billion CNY against total liabilities of 5.33 billion CNY, resulting in a net equity position of 32.46 billion CNY. Despite a negative operating cash flow of -328.69 million CNY, the firm generated positive free cash flow of 1.17 billion CNY, supported by capital expenditures of -379.02 million CNY. The valuation snapshot reflects a market capitalization of 29.67 billion CNY, trading at a price-to-book ratio of 0.91 and an EV/EBITDA of 13.76.
Profitability metrics show a return on equity of 6.17% and a return on assets of 5.30%, derived from a net income of 1.58 billion CNY on revenue of 7.35 billion CNY. The gross profit stands at 2.69 billion CNY, yielding a gross margin of approximately 36.6%, while operating income of 1.91 billion CNY suggests an operating margin of roughly 26.0%. These returns are generated within a capital-light operational framework, as evidenced by the low leverage and high asset base relative to debt.
- Strong liquidity position with a current ratio of 3.64 and low debt-to-equity of 0.12.
- Positive free cash flow of 1.17 billion CNY despite negative operating cash flow.
- Valuation appears attractive with a P/B ratio of 0.91 and P/E of 14.82.
- Low dilution risk with no difference between basic and diluted shares outstanding.
- Medium liquidity risk flagged due to negative net cash position after debt subtraction.
- Analyst consensus leans towards Buy with a mean recommendation of 2.00.
Bull / Bear case
Generated · model-assistedDebt-to-equity ratio of 0.12 is lower than the 0.18 cohort median, suggesting a conservative leverage profile.
The single analyst recommendation is a buy, providing positive sentiment despite limited coverage.
Cash conversion ratio of -0.16 places the company in the bottom quartile of its peer group.
A medium liquidity risk flag suggests potential challenges in meeting short-term financial obligations.
In focus — financials by report
Revenue ¥7.35B, −10,1% YoY; Operating income −28,4% YoY.
- ▍Revenue ¥7.35B, −10,1% YoY
- ▍Operating income −28,4% YoY
- ▍Net income −28,1% YoY
- ▍Free cash flow −24,6% YoY
- ▍Net margin 21.5%
Revenue ¥8.18B, +2,7% YoY; Operating income +20,1% YoY.
- ▍Revenue ¥8.18B, +2,7% YoY
- ▍Operating income +20,1% YoY
- ▍Net income +23,2% YoY
- ▍Free cash flow +20,7% YoY
- ▍Net margin 26.8%
Revenue ¥7.96B, +21,3% YoY; Operating income −2,4% YoY.
- ▍Revenue ¥7.96B, +21,3% YoY
- ▍Operating income −2,4% YoY
- ▍Net income −5,3% YoY
- ▍Free cash flow −21,7% YoY
- ▍Net margin 22.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Capmarket_price * shares_outstanding_diluted
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Ev To Operating Incomeenterprise_value / operating_income
- Shanghai RAAS Blood Products Co Ltd Market data — financials · 2026-07-08
- Shanghai RAAS Blood Products Co Ltd Market data — analyst estimates · 2026-07-08
- Shanghai RAAS Blood Products Co Ltd Market data — ESG · 2026-07-08